Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 18/20 | 1.00 |
| ▸ | SLC5A1 | P13866 | 11/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.77 |
| ▸ | SLC5A11 | Q8WWX8 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18573839 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL18685100 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL17189194 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL12285684 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL19620437 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL9611971 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL17189312 | 0.93 | SLC5A2 (0.86) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL17189322 | 0.92 | SLC5A2 (0.84) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL17189269 | 0.92 | SLC5A2 (0.84) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL19227110 | 0.92 | SLC5A2 (0.84) | SLC5A2SLC5A1ADRA2ASLC5A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230000816-A1 | SODIUM-GLUCOSE LINKED TRANSPORTER INHIBITORS FOR THE MANAGEMENT OF CHRONIC KIDNEY DISEASE, HYPERTENSION, AND HEART FAILURE IN COMPANION ANIMALS | INCREVET, INC. | 2023-01-05 | — | — | US | disclosed |
| EP-4054556-A1 | SODIUM-GLUCOSE LINKED TRANSPORTER INHIBITORS FOR THE MANAGEMENT OF CHRONIC KIDNEY DISEASE, HYPERTENSION, AND HEART FAILURE IN COMPANION ANIMALS | Increvet, Inc. (US) | 2022-09-14 | — | — | EP | disclosed |
| WO-2022062401-A1 | PREPARATION METHOD FOR TIANAGLIFLOZIN | 广州市力鑫药业有限公司 | 2022-03-31 | — | — | WO | disclosed |
| EP-2457918-A2 | Crystalline solvates and complexes of (1s)-1,5-anhydro-1-c-(3-((phenyl) methyl) phenyl)-d-glucitol derivatives with amino acids as SGLT2 inhibitors for the treatment of diabetes | Bristol-Myers Squibb Company (US) | 2012-05-30 | — | — | EP | disclosed |
| WO-2008116179-A1 | PHARMACEUTICAL FORMULATIONS CONTAINING DAPAGLIFLOZIN PROPYLENE GLYCOL HYDRATE | BRISTOL-MYERS SQUIBB (US) | 2008-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230000816-A1 | SODIUM-GLUCOSE LINKED TRANSPORTER INHIBITORS FOR THE MANAGEMENT OF CHRONIC KIDNEY DISEASE, HYPERTENSION, AND HEART FAILURE IN COMPANION ANIMALS | SLC5A1, SLC5A2, SLC2A1 | SLC5A2 2/4885SLC5A1 1/4885ADRA2A 1876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.